Logo image of AGEN

AGENUS INC (AGEN) Stock Fundamental Analysis

NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD

5.36  -0.16 (-2.9%)

After market: 5.698 +0.34 (+6.31%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to AGEN. AGEN was compared to 553 industry peers in the Biotechnology industry. Both the profitability and financial health of AGEN have multiple concerns. AGEN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AGEN has reported negative net income.
In the past year AGEN has reported a negative cash flow from operations.
AGEN had negative earnings in each of the past 5 years.
In the past 5 years AGEN reported 4 times negative operating cash flow.
AGEN Yearly Net Income VS EBIT VS OCF VS FCFAGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

AGEN has a worse Return On Assets (-95.31%) than 74.32% of its industry peers.
Industry RankSector Rank
ROA -95.31%
ROE N/A
ROIC N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGEN Yearly ROA, ROE, ROICAGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

AGEN has a better Gross Margin (99.48%) than 99.10% of its industry peers.
AGEN's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for AGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
AGEN Yearly Profit, Operating, Gross MarginsAGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGEN has been increased compared to 1 year ago.
The number of shares outstanding for AGEN has been increased compared to 5 years ago.
Compared to 1 year ago, AGEN has a worse debt to assets ratio.
AGEN Yearly Shares OutstandingAGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AGEN Yearly Total Debt VS Total AssetsAGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -17.62, we must say that AGEN is in the distress zone and has some risk of bankruptcy.
AGEN has a worse Altman-Z score (-17.62) than 82.46% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.62
ROIC/WACCN/A
WACC9.07%
AGEN Yearly LT Debt VS Equity VS FCFAGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

2.3 Liquidity

A Current Ratio of 0.11 indicates that AGEN may have some problems paying its short term obligations.
The Current ratio of AGEN (0.11) is worse than 96.93% of its industry peers.
AGEN has a Quick Ratio of 0.11. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.11, AGEN is doing worse than 96.75% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
AGEN Yearly Current Assets VS Current LiabilitesAGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

AGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.48%, which is quite impressive.
AGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -38.34%.
The Revenue has been decreasing by -7.17% on average over the past years.
EPS 1Y (TTM)32.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.12%
Revenue 1Y (TTM)-38.34%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%-14.07%

3.2 Future

AGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.13% yearly.
Based on estimates for the next years, AGEN will show a quite strong growth in Revenue. The Revenue will grow by 17.51% on average per year.
EPS Next Y104.65%
EPS Next 2Y37.03%
EPS Next 3Y20.8%
EPS Next 5Y14.13%
Revenue Next Year19.44%
Revenue Next 2Y5.12%
Revenue Next 3Y-0.36%
Revenue Next 5Y17.51%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AGEN Yearly Revenue VS EstimatesAGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AGEN Yearly EPS VS EstimatesAGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGEN Price Earnings VS Forward Price EarningsAGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGEN Per share dataAGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as AGEN's earnings are expected to grow with 20.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.03%
EPS Next 3Y20.8%

More info and screens

0

5. Dividend

5.1 Amount

AGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGENUS INC

NASDAQ:AGEN (8/1/2025, 8:19:27 PM)

After market: 5.698 +0.34 (+6.31%)

5.36

-0.16 (-2.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners34%
Inst Owner Change-0.16%
Ins Owners1.43%
Ins Owner Change0.43%
Market Cap146.97M
Analysts76.36
Price Target11.73 (118.84%)
Short Float %8.42%
Short Ratio1.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.15%
Min EPS beat(2)21.32%
Max EPS beat(2)38.98%
EPS beat(4)2
Avg EPS beat(4)-10.11%
Min EPS beat(4)-71.27%
Max EPS beat(4)38.98%
EPS beat(8)5
Avg EPS beat(8)-19.56%
EPS beat(12)7
Avg EPS beat(12)-11.56%
EPS beat(16)9
Avg EPS beat(16)-10.26%
Revenue beat(2)0
Avg Revenue beat(2)-11.82%
Min Revenue beat(2)-13.08%
Max Revenue beat(2)-10.55%
Revenue beat(4)0
Avg Revenue beat(4)-28.15%
Min Revenue beat(4)-62.51%
Max Revenue beat(4)-10.55%
Revenue beat(8)2
Avg Revenue beat(8)-8.72%
Revenue beat(12)5
Avg Revenue beat(12)0.14%
Revenue beat(16)7
Avg Revenue beat(16)3.55%
PT rev (1m)0%
PT rev (3m)91.67%
EPS NQ rev (1m)218.71%
EPS NQ rev (3m)207.98%
EPS NY rev (1m)115.84%
EPS NY rev (3m)112.08%
Revenue NQ rev (1m)94.1%
Revenue NQ rev (3m)89.32%
Revenue NY rev (1m)11.2%
Revenue NY rev (3m)20.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.67
EYN/A
EPS(NY)-1.31
Fwd EYN/A
FCF(TTM)-5.34
FCFYN/A
OCF(TTM)-5.32
OCFYN/A
SpS3.63
BVpS-12.47
TBVpS-13.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.48%
FCFM N/A
ROA(3y)-77.38%
ROA(5y)-64.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5YN/A
F-Score2
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.15%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -17.62
F-Score2
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)280.5%
Cap/Depr(5y)277.58%
Cap/Sales(3y)20.35%
Cap/Sales(5y)15.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.12%
EPS Next Y104.65%
EPS Next 2Y37.03%
EPS Next 3Y20.8%
EPS Next 5Y14.13%
Revenue 1Y (TTM)-38.34%
Revenue growth 3Y-29.53%
Revenue growth 5Y-7.17%
Sales Q2Q%-14.07%
Revenue Next Year19.44%
Revenue Next 2Y5.12%
Revenue Next 3Y-0.36%
Revenue Next 5Y17.51%
EBIT growth 1Y24.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.17%
EBIT Next 3Y-10.15%
EBIT Next 5Y-10.98%
FCF growth 1Y36.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.7%
OCF growth 3YN/A
OCF growth 5YN/A